Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) will publish fourth-quarter and fiscal 2025 financial results and deliver a business update on March 12, 2026. The company develops in vivo gene editing therapies using its proprietary ARCUS platform for high unmet-need diseases. Investors can expect results and management commentary on that date.
Precision BioSciences (Nasdaq: DTIL) announced the U.S. FDA granted Fast Track designation to PBGENE-DMD for treating Duchenne muscular dystrophy (DMD) and that it will host a virtual investor/KOL event on March 17, 2026 to discuss PBGENE-DMD and the planned Phase 1/2 FUNCTION-DMD study.
The company said Fast Track aims to facilitate development and expedite review, and noted recent IND clearance supporting PBGENE-DMD’s advancement toward clinical investigation in boys living with DMD.
Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.
The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.
Precision BioSciences (Nasdaq: DTIL) announced that new preclinical data for PBGENE-DMD was selected for a poster at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, March 8-11, 2026.
The poster, titled "PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model" (Publication 142M), is scheduled for presentation on Monday, March 9, 2026.
Precision BioSciences (Nasdaq: DTIL) received a U.S. FDA Study May Proceed notification for its PBGENE-DMD IND, enabling IRB activities and clinical site activation for the FUNCTION-DMD Phase 1/2 study.
PBGENE-DMD is a one-time in vivo gene excision therapy targeting mutations between exons 45–55 (≈60% of DMD patients) intended to restore near full-length dystrophin (~80% of full length). The company plans a March virtual event with KOLs and patient advocates and aims to activate the first U.S. clinical site in H1 2026.
Precision BioSciences (Nasdaq: DTIL) outlined 2026 strategic priorities focused on advancing two clinical-stage gene editing programs: PBGENE-HBV (Phase 1/2a ELIMINATE-B) with dose-finding cohorts ongoing and additional biopsy data expected in H1 2026, and PBGENE-DMD with IND clearance expected in Q1 2026 and first dosing planned for late-Q1/early-Q2 2026 with initial multi-patient data expected by year-end 2026. The company reported unaudited $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025, which management expects to fund key data milestones through 2028. Partnered programs include ECUR-506 (iECURE) and azer-cel (Imugene, TG Therapeutics), and Precision received an $8 million milestone in Q4 2025.
iECURE (DTIL) announced that the FDA granted RMAT designation to ECUR-506 for neonatal onset ornithine transcarbamylase (OTC) deficiency, enabling intensified FDA interaction and expedited review.
The company said it aligned with the FDA on primary and key secondary endpoints, comparators, and sample size for the ongoing OTC-HOPE study, which could support a Biologics License Application (BLA). ECUR-506 also received an Innovation Passport under the UK’s relaunched ILAP. iECURE reported a complete clinical response in the first infant treated in OTC-HOPE and holds prior Rare Pediatric Disease and Orphan Drug designations.
Precision BioSciences (Nasdaq: DTIL) announced that on Dec 9, 2025 its Compensation Committee approved an inducement award of 8,224 restricted stock units (RSUs) for a newly hired employee under the company's 2021 Employment Inducement Incentive Award Plan.
The RSUs were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement to commence employment and vest in substantially equal annual installments on each of the first three anniversaries of the employee's start date, subject to continued service.
Precision BioSciences (Nasdaq: DTIL) will present clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV at Hep-DART 2025 in Honolulu, December 7–11, 2025.
The oral presentation titled “PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, demonstrates safety and antiviral activity across three cohorts” is scheduled for Tuesday, December 9, 4:45pm HST and will be presented by Man-Fung Yuen, MBBS, MD, PhD, DSc, with authorship including Cassandra L. Gorsuch and others.
The announcement emphasizes Phase 1 clinical results on safety and antiviral activity for an in vivo ARCUS® gene editing candidate targeting viral templates that drive chronic hepatitis B.
Precision BioSciences (Nasdaq: DTIL) announced an underwritten offering expected to raise approximately $75 million in gross proceeds by selling 10,815,000 common shares, pre-funded warrants to purchase 1,400,000 shares and accompanying warrants.
The per-unit price is $6.14 (pre-funded at $6.139995); each whole warrant has a $7.25 exercise price, is exercisable immediately and expires five years after issuance. The offering is expected to close on or about November 12, 2025, and proceeds will fund R&D, working capital and general corporate purposes.